This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
Certain corners of the healthcare AI industry continue hyping the notion that their technology will render physicians unneeded. Young people, including potential medical students, might believe the claim. Here’s help.
During the COVID-19 pandemic, telehealth provider HealthTap began to emphasize its ability to deliver primary care services. Now, the group’s Co-Founder and CEO Sean Mehra says long-term patient care delivered from anywhere has become its central focus, as advancements in technology made it a reality.
Earlier this year Congress extended CMS’s hospital-at-home waiver for five years via the Consolidated Appropriations Act of 2026. With that bold stroke, ‘HaH’ services became eligible for Medicare reimbursement through September of 2030.
The cardiovascular care of thousands of Missouri patients is suddenly up in the air. The heart of the issue is a practice's alleged interest in opening up a new private equity-backed clinic.
Clinlab.AI will oversee every aspect of this new-look laboratory, working to integrate it with the practice's workflows in a way that boosts patient care and speeds up treatment decisions.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Neurosurgeon Vitor Mendes Pereira, MD, was in Santiago, Panama, but his patient was in Panama City. "It is the highlight of my career to be involved in this historic achievement," Pereira said.
A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.
The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.